PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8634684-0	1995	Participation of TNF-alpha and IL-1 in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis.	Cyclophosphamide	59-75	interleukin 1 complex	Mus musculus	31-35	
9096241-4	1997	Supernatants collected from P388D1 cells treated with CA, VS, CS, MMC, HU or LPS demonstrated enhanced production of tumor necrosis factor (TNF) confirmed by bioassay on L929 tumor target cells and increased interleukin-1 (IL-1) production by standard thymocyte proliferation bioassay.	Cyclophosphamide	62-64	interleukin 1 complex	Mus musculus	208-227	
8886850-1	1996	Alkylating agents, cyclophosphamide (CY) and the related compound mechlorethamine (NM), significantly increase in vivo the blood level of IL-6 but not of IL-1.	Cyclophosphamide	19-35	interleukin 1 complex	Mus musculus	154-158	
8886850-1	1996	Alkylating agents, cyclophosphamide (CY) and the related compound mechlorethamine (NM), significantly increase in vivo the blood level of IL-6 but not of IL-1.	Cyclophosphamide	37-39	interleukin 1 complex	Mus musculus	154-158	
12205906-4	1999	The results also showed that PLGC could restore the capacity of macrophage for secreting IL-1 that had been inhibited by cyclophosphamide and PLGC could enhance the release of IL-2 from spleen cell in the experiment group (P < 0.05-0.01).	Cyclophosphamide	121-137	interleukin 1 complex	Mus musculus	89-93	
9673408-2	1998	Similarly, IL-1 is reported to accelerate recovery following myelosuppressive treatment with doxorubicin (AdR), cis-platinum (DDP) and cyclophosphamide (CTx).	Cyclophosphamide	135-151	interleukin 1 complex	Mus musculus	11-15	
8176939-3	1994	This antitumor effect was abolished when administration of CPA preceded that of IL-1.	Cyclophosphamide	59-62	interleukin 1 complex	Mus musculus	80-84	
1290956-7	1992	While IL-1 and TNF-alpha stimulate both of these enzymes, other mechanisms are probably also operative for other forms of chemotherapy, i.e. IL-1 and TNF-alpha were shown to protect hematopoietic progenitors from phenylketophosphamide, a cyclophosphamide derivative that is not metabolized by the enzyme aldehyde dehydrogenase.	Cyclophosphamide	238-254	interleukin 1 complex	Mus musculus	6-10	
1290956-7	1992	While IL-1 and TNF-alpha stimulate both of these enzymes, other mechanisms are probably also operative for other forms of chemotherapy, i.e. IL-1 and TNF-alpha were shown to protect hematopoietic progenitors from phenylketophosphamide, a cyclophosphamide derivative that is not metabolized by the enzyme aldehyde dehydrogenase.	Cyclophosphamide	238-254	interleukin 1 complex	Mus musculus	141-145	
2144844-2	1990	In normal mice and in mice pretreated with cyclophosphamide, hydrocortisone acetate, or sublethal total body irradiation, the outgrowth of Candida albicans in the kidney was significantly reduced by the administration of a single intraperitoneal dose of 80 ng of IL-1 (P less than 0.05).	Cyclophosphamide	43-59	interleukin 1 complex	Mus musculus	263-267	
1761361-2	1991	Intact or cyclophosphamide-treated mice received human rIL-1 beta according to different regimens, and their sera were assayed for CSA at 4, 24 or 48 h. The results indicated that (1) cyclophosphamide alone significantly increased the level of circulating CSA, (2) administration of IL-1 to intact or neutropenic mice resulted in a biphasic pattern of CSA response, an early burst at 4 h being followed at 24-48 h by a significant decrease.	Cyclophosphamide	10-26	interleukin 1 complex	Mus musculus	56-60	
2144844-3	1990	In mice treated with either cyclophosphamide or irradiation, IL-1 also significantly reduced the outgrowth of C. albicans in the spleen.	Cyclophosphamide	28-44	interleukin 1 complex	Mus musculus	61-65	
2144844-4	1990	The protective effect of IL-1 was present when given 24 h before injection of C. albicans but also when IL-1 was given simultaneously with or 6 h after injection of C. albicans in cyclophosphamide-treated mice.	Cyclophosphamide	180-196	interleukin 1 complex	Mus musculus	25-29	
2144844-4	1990	The protective effect of IL-1 was present when given 24 h before injection of C. albicans but also when IL-1 was given simultaneously with or 6 h after injection of C. albicans in cyclophosphamide-treated mice.	Cyclophosphamide	180-196	interleukin 1 complex	Mus musculus	104-108	
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclophosphamide	67-83	interleukin 1 complex	Mus musculus	193-197	
1966937-6	1990	Production of interleukin 1 (IL-1) was also stimulated in sera of CY-treated and untreated mice by administration of GLA-60.	Cyclophosphamide	66-68	interleukin 1 complex	Mus musculus	14-33	
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclophosphamide	67-83	interleukin 1 complex	Mus musculus	379-383	
2783314-6	1989	Both neutrophilia and augmented resistance to infection were eliminated by a second dose of cyclophosphamide administered during the IL-1 treatments.	Cyclophosphamide	92-108	interleukin 1 complex	Mus musculus	133-137	
2643663-7	1989	IL-1 effects were observed in mice treated with a wide dose range (50 to 300 mg/kg) of cyclophosphamide, with optimal effects occurring at a dose of 200 mg/kg.	Cyclophosphamide	87-103	interleukin 1 complex	Mus musculus	0-4	
2317799-9	1990	Enhanced antibacterial resistance by IL-1 and OK432 was also observed in cyclophosphamide- and aminomethylpyrimidinylmethylchloroethylnitrosourea hydrochloride-pretreated (day -5) normal hosts and in cyclophosphamide-treated tumor-bearing hosts.	Cyclophosphamide	73-89	interleukin 1 complex	Mus musculus	37-41	
2317799-9	1990	Enhanced antibacterial resistance by IL-1 and OK432 was also observed in cyclophosphamide- and aminomethylpyrimidinylmethylchloroethylnitrosourea hydrochloride-pretreated (day -5) normal hosts and in cyclophosphamide-treated tumor-bearing hosts.	Cyclophosphamide	200-216	interleukin 1 complex	Mus musculus	37-41	
2806435-1	1989	Previous reports have shown that interleukin 1 (IL-1) has radioprotective effects when given to mice 20 h before a lethal dose of irradiation and enhances granulocyte recovery in mice treated with cyclophosphamide.	Cyclophosphamide	197-213	interleukin 1 complex	Mus musculus	33-52	
2784143-1	1989	Based on recently published data, IL-1 has been shown to provide radioprotective effects when given to mice 20 h before a lethal dose of irradiation and to enhance granulocyte recovery in mice treated with cyclophosphamide.	Cyclophosphamide	206-222	interleukin 1 complex	Mus musculus	34-38	
19703244-3	2009	However, when the mice were pretreated with cyclophosphamide, bacteremia-induced mortality was significantly greater in the IL-1-deficient mice than in the WT mice (P < 0.01).	Cyclophosphamide	44-60	interleukin 1 complex	Mus musculus	124-128